Search
Cullinan Therapeutics' CEO Nadim Ahmed covers last week's #ASCO25 data for zipalertinib in EGFRex20 insertion lung cancer, plus an in-depth conversation about bispecifics for autoimmune conditions
He highlights the zipalertinib ASCO data, which was in the relapsed setting and will be used by Cullinan's partner, Taiho, to file for...
Jun 10
The CEO of Cullinan Therapeutics discusses two data sets at #ASCO24 and the rationale for a T-cell engager for autoimmune disease
Nadim Ahmed describes #ASCO24 data from today for CLN-619 and zipalertinib, and discusses taking a CD19/CD3 into the clinic for lupus.
Jun 1, 2024
Talking oncology targets (EGFR, FLT3, B7H4 and more) with Cullinan Oncology
Cullinan Oncology CEO Nadim Ahmed walks us through the oncology targets the company is focused on and discusses recent ASCO data.
Jun 7, 2023
.png){kind=logo}
